Journal of Clinical Oncology, Vol 15, 2090-2096, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group

A Ardizzoni, H Hansen, P Dombernowsky, T Gamucci, S Kaplan, P Postmus, G Giaccone, B Schaefer, J Wanders and J Verweij
Department of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

PURPOSE: To assess activity and toxicity of topotecan in previously treated small-cell lung cancer (SCLC) patients. PATIENTS AND METHODS: Patients with measurable SCLC, progressive after one first-line regimen, were eligible for the study. Two groups of patients were selected: (1) patients who failed first-line treatment < or = 3 months from chemotherapy discontinuation (refractory group); and (2) patients who responded to first-line treatment and progressed greater than 3 months after chemotherapy discontinuation (sensitive group). Topotecan was administered as a 30-minute daily infusion at a dose of 1.5 mg/m2 for 5 consecutive days, every 3 weeks. RESULTS: One hundred one patients were entered onto the study and 403 courses were administered. Ninety-two patients (47 refractory and 45 sensitive) were eligible and assessable for response. Among refractory patients, there were two partial responses (PRs) and one complete response (CR), for an overall response rate of 6.4% (95% confidence interval [CI], 1.3% to 17.6%), whereas in the sensitive group, there were 11 PRs and six CRs, for an overall response rate of 37.8% (95% CI, 23.8% to 53.5%). Overall median duration of response was 7.6 months. Median survival was 5.4 months; median survival of refractory patients was 4.7 months, whereas that of sensitive patients was 6.9 months (P = .002). Median survival of responding patients was 12.5 months. Toxicity was mainly hematologic. Leukopenia, although short-lived, was universal, with grade III and IV neutropenia occurring in 28% and 46.8% of cycles, respectively. Nonhematological toxicity was mild. Fatigue/malaise was reported in 39.3% of cycles and transient elevation of liver enzymes in 17%. CONCLUSION: Topotecan has significant activity in SCLC, particularly in patients sensitive to prior chemotherapy, with predictable and manageable toxicity. The incorporation of topotecan in combination chemotherapy regimens for future treatment of SCLC is warranted.

This article has been cited by other articles:

				A. Inoue, S. Sugawara, K. Yamazaki, M. Maemondo, T. Suzuki, K. Gomi, S. Takanashi, C. Inoue, M. Inage, H. Yokouchi, et al. Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402 J. Clin. Oncol., November 20, 2008; 26(33): 5401 - 5406. [Abstract] [Full Text] [PDF]

				D. H. Lee, S.-W. Kim, C. Suh, J.-S. Lee, J. H. Lee, S.-J. Lee, B. Y. Ryoo, K. Park, J. S. Kim, D. S. Heo, et al. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study Ann. Onc., January 1, 2008; 19(1): 123 - 127. [Abstract] [Full Text] [PDF]

				M. O'Brien, J. Eckardt, and R. Ramlau Recent Advances with Topotecan in the Treatment of Lung Cancer Oncologist, October 1, 2007; 12(10): 1194 - 1204. [Abstract] [Full Text] [PDF]

				D. J. Samson, J. Seidenfeld, G. R. Simon, A. T. Turrisi III, C. Bonnell, K. M. Ziegler, and N. Aronson Evidence for Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 314S - 323S. [Abstract] [Full Text] [PDF]

				J. R. Eckardt, J. von Pawel, J.-L. Pujol, Z. Papai, E. Quoix, A. Ardizzoni, R. Poulin, A. J. Preston, G. Dane, and G. Ross Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer J. Clin. Oncol., May 20, 2007; 25(15): 2086 - 2092. [Abstract] [Full Text] [PDF]

				M. E.R. O'Brien, T.-E. Ciuleanu, H. Tsekov, Y. Shparyk, B. Cucevia, G. Juhasz, N. Thatcher, G. A. Ross, G. C. Dane, and T. Crofts Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer J. Clin. Oncol., December 1, 2006; 24(34): 5441 - 5447. [Abstract] [Full Text] [PDF]

				S. Onoda, N. Masuda, T. Seto, K. Eguchi, Y. Takiguchi, H. Isobe, H. Okamoto, T. Ogura, A. Yokoyama, N. Seki, et al. Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301 J. Clin. Oncol., December 1, 2006; 24(34): 5448 - 5453. [Abstract] [Full Text] [PDF]

				R. M. Huber, M. Reck, H. Gosse, J. von Pawel, J. Mezger, J. G. Saal, R. Kleinschmidt, C. Steppert, and H. Steppling Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer Eur. Respir. J., June 1, 2006; 27(6): 1183 - 1189. [Abstract] [Full Text] [PDF]

				G. K. Dy, A. A. Miller, S. J. Mandrekar, M.-C. Aubry, R. M. Langdon Jr., R. F. Morton, S. E. Schild, J. R. Jett, and A. A. Adjei A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study Ann. Onc., November 1, 2005; 16(11): 1811 - 1816. [Abstract] [Full Text] [PDF]

				D. K. Armstrong, D. Spriggs, J. Levin, R. Poulin, and S. Lane Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis Oncologist, October 1, 2005; 10(9): 686 - 694. [Abstract] [Full Text] [PDF]

				H. S Sano, J A. Waddell, D. A Solimando Jr, P. Doulaveris, and R. Myhand Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost Journal of Oncology Pharmacy Practice, March 1, 2005; 11(1): 21 - 30. [Abstract] [PDF]

				A. Ardizzoni Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update Oncologist, December 1, 2004; 9(suppl_6): 4 - 13. [Abstract] [Full Text] [PDF]

				R. J. Gralla Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life Oncologist, December 1, 2004; 9(suppl_6): 14 - 24. [Abstract] [Full Text] [PDF]

				J. R. Eckardt Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer Oncologist, December 1, 2004; 9(suppl_6): 25 - 32. [Abstract] [Full Text] [PDF]

				D. J. Stewart Topotecan in the First-Line Treatment of Small Cell Lung Cancer Oncologist, December 1, 2004; 9(suppl_6): 33 - 42. [Abstract] [Full Text] [PDF]

				J. V. Heymach, D. H. Johnson, F. R. Khuri, H. Safran, L. L. Schlabach, F. Yunus, R. F. DeVore III, P. M. De Porre, H. M. Richards, X. Jia, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer Ann. Onc., August 1, 2004; 15(8): 1187 - 1193. [Abstract] [Full Text] [PDF]

				A. Iop, A. M. Manfredi, and S. Bonura Fatigue in cancer patients receiving chemotherapy: an analysis of published studies Ann. Onc., May 1, 2004; 15(5): 712 - 720. [Abstract] [Full Text] [PDF]

				J. Treat, C. H. Huang, S. R. Lane, and J. Levin Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status Oncologist, April 1, 2004; 9(2): 173 - 181. [Abstract] [Full Text] [PDF]

				E. T. Wong and A. Berkenblit The Role of Topotecan in the Treatment of Brain Metastases Oncologist, February 1, 2004; 9(1): 68 - 79. [Abstract] [Full Text] [PDF]

				A. Spira and D. S. Ettinger Multidisciplinary Management of Lung Cancer N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392. [Full Text] [PDF]

				B. H. Kushner, K. Kramer, S. Modak, and N.-K. V. Cheung Camptothecin Analogs (Irinotecan or Topotecan) plus High-Dose Cyclophosphamide as Preparative Regimens for Antibody-Based Immunotherapy in Resistant Neuroblastoma Clin. Cancer Res., January 1, 2004; 10(1): 84 - 87. [Abstract] [Full Text] [PDF]

				B. E. Johnson, T. Fischer, B. Fischer, D. Dunlop, D. Rischin, S. Silberman, M. O. Kowalski, D. Sayles, S. Dimitrijevic, C. Fletcher, et al. Phase II Study of Imatinib in Patients with Small Cell Lung Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5880 - 5887. [Abstract] [Full Text] [PDF]

				E. Felip, R. Rosell, M. Domine, L. Santome, P. Garrido, A. Font, A. Carrato, J. Terrasa, C. Vadell, J. M. Mane, et al. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study Ann. Onc., October 1, 2003; 14(10): 1549 - 1554. [Abstract] [Full Text] [PDF]

				M. Beran, S. O'Brien, D. A. Thomas, H. T. Tran, J. E. Cortes-Franco, F. Giles, E. Estey, and H. M. Kantarjian Phase I Study of Oral Topotecan in Hematological Malignancies Clin. Cancer Res., September 15, 2003; 9(11): 4084 - 4091. [Abstract] [Full Text] [PDF]

				C. Lu, R. Komaki, J. S. Lee, D. M. Shin, J. L. Palmer, B. J. Coldman, K. M. Pisters, J. M. Kurie, F. V. Fossella, and B. S. Glisson A Phase I Study of Topotecan/Paclitaxel Alternating with Etoposide/Cisplatin and Thoracic Irradiation in Patients with Limited Small Cell Lung Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2085 - 2091. [Abstract] [Full Text] [PDF]

				G. A. Masters, L. Declerck, C. Blanke, A. Sandler, R. DeVore, K. Miller, and D. Johnson Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597 J. Clin. Oncol., April 15, 2003; 21(8): 1550 - 1555. [Abstract] [Full Text] [PDF]

				F. J. Giles, S. Faderl, D. A. Thomas, J. E. Cortes, G. Garcia-Manero, D. Douer, A. M. Levine, C. A. Koller, S. S. Jeha, S. M. O'Brien, et al. Randomized Phase I/II Study of Troxacitabine Combined With Cytarabine, Idarubicin, or Topotecan in Patients With Refractory Myeloid Leukemias J. Clin. Oncol., March 15, 2003; 21(6): 1050 - 1056. [Abstract] [Full Text] [PDF]

				W. West, R. Birch, F. Schnell, J. Hainsworth, J. Tongol, and L. Campos Phase I Study of Paclitaxel and Topotecan for the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer Oncologist, February 1, 2003; 8(1): 76 - 82. [Abstract] [Full Text] [PDF]

				A. Ardizzoni, C. Manegold, C. Debruyne, R. Gaafar, E. Buchholz, E. F. Smit, P. Lianes, G. ten Velde, L. Bosquee, C. Legrand, et al. European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer Clin. Cancer Res., January 1, 2003; 9(1): 143 - 150. [Abstract] [Full Text] [PDF]

				S. H. Okuno and J. R. Jett Small Cell Lung Cancer: Current Therapy and Promising New Regimens Oncologist, June 1, 2002; 7(3): 234 - 238. [Abstract] [Full Text] [PDF]

				C. M. Rudin, G. A. Otterson, A. M. Mauer, M. A. Villalona-Calero, R. Tomek, B. Prange, C. M. George, L. Szeto, and E. E. Vokes A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer Ann. Onc., April 1, 2002; 13(4): 539 - 545. [Abstract] [Full Text] [PDF]

				R. Garcia-Carbonero and J. G. Supko Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661. [Abstract] [Full Text] [PDF]

				J. von Pawel, U. Gatzemeier, J.-L. Pujol, L. Moreau, S. Bildat, M. Ranson, G. Richardson, C. Steppert, A. Riviere, I. Camlett, et al. Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer J. Clin. Oncol., March 15, 2001; 19(6): 1743 - 1749. [Abstract] [Full Text] [PDF]

				M. J. A. de Jonge, W. J. Loos, H. Gelderblom, A. S. Th. Planting, M. E. L. van der Burg, A. Sparreboom, E. Brouwer, V. van Beurden, M. A. Mantel, E. Doyle, et al. Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects J. Clin. Oncol., May 10, 2000; 18(10): 2104 - 2115. [Abstract] [Full Text] [PDF]

				K. Kelly New Chemotherapy Agents for Small Cell Lung Cancer Chest, April 1, 2000; 117(4_suppl_1): 156S - 162S. [Abstract] [Full Text] [PDF]

				J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]

				M. J.A. de Jonge, C. J.A. Punt, A. H. Gelderblom, W. J. Loos, V. van Beurden, A. S.Th. Planting, M. E.L. van der Burg, L. W.G.M. van Maanen, B. K. Dallaire, J. Verweij, et al. Phase I and Pharmacologic Study of Oral (PEG-1000) 9-Aminocamptothecin in Adult Patients With Solid Tumors J. Clin. Oncol., July 1, 1999; 17(7): 2219 - 2219. [Abstract] [Full Text] [PDF]

				H. J.M. Groen, E. Fokkema, B. Biesma, B. Kwa, J. W.G. van Putten, P. E. Postmus, and E. F. Smit Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule J. Clin. Oncol., March 1, 1999; 17(3): 927 - 927. [Abstract] [Full Text] [PDF]

				J. von Pawel, J. H. Schiller, F. A. Shepherd, S. Z. Fields, J.P. Kleisbauer, N. G. Chrysson, D. J. Stewart, P. I. Clark, M. C. Palmer, A. Depierre, et al. Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer J. Clin. Oncol., February 1, 1999; 17(2): 658 - 658. [Abstract] [Full Text] [PDF]

				C. J. H. Gerrits, J. H. M. Schellens, H. Burris, J. R. Eckardt, A. S. T. Planting, M. E. L. van der Burg, G. I. Rodriguez, W. J. Loos, V. van Beurden, I. Hudson, et al. A Comparison of Clinical Pharmacodynamics of Different Administration Schedules of Oral Topotecan (Hycamtin) Clin. Cancer Res., January 1, 1999; 5(1): 69 - 75. [Abstract] [Full Text] [PDF]

				J.-F. Héron Topotecan: An Oncologist's View Oncologist, December 1, 1998; 3(6): 390 - 402. [Abstract] [Full Text]

				H. A. Burris III Topotecan: Incorporating It Into the Treatment of Solid Tumors Oncologist, February 1, 1998; 3(1): 1 - 3. [Full Text]

				J. R. Brahmer and D. S. Ettinger The Role of Topotecan in the Treatment of Small Cell Lung Cancer Oncologist, February 1, 1998; 3(1): 11 - 14. [Abstract] [Full Text]

				V. Relias and J. Andrew Skirvin Review : Topoisomerase I inhibitors: 1. Topotecan Journal of Oncology Pharmacy Practice, December 1, 1997; 3(4): 173 - 185. [Abstract] [PDF]